Momenta Pharmaceuticals (NASDAQ:MNTA) reported Q4 2017 earnings this Morning, coming in at $0.18 per share, beating Wall Street’s estimates of ($0.18) per Share. Revenue for the quarter came in at $64.60 million missing the streets estimates of $66.59 million Recent Insider Trading for Momenta Pharmaceuticals (NASDAQ:MNTA)
- On 2/14/2018 Bruce Leicher, SVP, sold 4,948 with an average share price of $15.22 per share and the total transaction amounting to $75,308.56.
- On 2/14/2018 Craig A Wheeler, CEO, sold 18,648 with an average share price of $16.14 per share and the total transaction amounting to $300,978.72.
- On 2/14/2018 Ganesh Venkataraman Kaundinya, COO, sold 4,986 with an average share price of $15.23 per share and the total transaction amounting to $75,936.78.
- On 2/14/2018 Scott M. Storer, CFO, sold 3,972 with an average share price of $15.16 per share and the total transaction amounting to $60,215.52.
- On 2/12/2018 Bruce Leicher, SVP, sold 309 with an average share price of $16.20 per share and the total transaction amounting to $5,005.80.
- On 2/12/2018 Craig A Wheeler, CEO, sold 1,773 with an average share price of $16.18 per share and the total transaction amounting to $28,687.14.
Recent Trading for Momenta Pharmaceuticals (NASDAQ:MNTA) Shares of Momenta Pharmaceuticals closed the previous trading session at 16.70 up +0.75 4.70% with 15.899999618530273 shares trading hands.